EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeting factor XI and factor XIa to prevent thrombosis

David Gailani iD, Andras Gruber iD

Blood · 11.04.2024 · 143 (15) · 1465-1475

DOI: 10.1182/blood.2023020722 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood, erschienen am 11.04.2024. Verfasst von David Gailani und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN. Hauptthemen laut MEDLINE: Factor XI, Thrombosis. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Direct oral anticoagulants (DOACs) that inhibit the coagulation proteases thrombin or factor Xa (FXa) have replaced warfarin and other vitamin K antagonists (VKAs) for most indications requiring long-term anticoagulation. In many clinical situations, DOACs are as effective as VKAs, cause less bleeding, and do not require laboratory monitoring. However, because DOACs target proteases that are required for hemostasis, their use increases the risk of serious bleeding. Concerns over therapy-related bleeding undoubtedly contribute to undertreatment of many patients who would benefit from anticoagulation therapy. There is considerable interest in the plasma zymogen factor XI (FXI) and its protease form factor XIa (FXIa) as drug targets for treating and preventing thrombosis. Laboratory and epidemiologic studies support the conclusion that FXI contributes to venous and arterial thrombosis. Based on 70 years of clinical observations of patients lacking FXI, it is anticipated that drugs targeting this protein will cause less severe bleeding than warfarin or DOACs. In phase 2 studies, drugs that inhibit FXI or FXIa prevent venous thromboembolism after total knee arthroplasty as well as, or better than, low molecular weight heparin. Patients with heart disease on FXI or FXIa inhibitors experienced less bleeding than patients taking DOACs. Based on these early results, phase 3 trials have been initiated that compare drugs targeting FXI and FXIa to standard treatments or placebo. Here, we review the contributions of FXI to normal and abnormal coagulation and discuss results from preclinical, nonclinical, and clinical studies of FXI and FXIa inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor XIThrombosisHumansFactor XIaWarfarinBlood CoagulationAnticoagulantsHemorrhageFibrinolytic Agents

Substanzen

Factor XIFactor XIaWarfarinAnticoagulantsFibrinolytic Agents

Autor:innen und Institutionen

  • The Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
  • Aronora, Inc, Portland, OR.

ORCID-Profile: David Gailani, Andras Gruber

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Gailani, D., & Gruber, A. (2024). Targeting factor XI and factor XIa to prevent thrombosis. Blood, 143(15), 1465-1475. https://doi.org/10.1182/blood.2023020722

Vancouver

Gailani D, Gruber A. Targeting factor XI and factor XIa to prevent thrombosis. Blood. 2024;143(15):1465-1475. doi:10.1182/blood.2023020722

BibTeX
@article{Gailani2024,
  author = {Gailani, David and Gruber, Andras},
  title = {Targeting factor XI and factor XIa to prevent thrombosis},
  journal = {Blood},
  year = {2024},
  volume = {143},
  number = {15},
  pages = {1465--1475},
  doi = {10.1182/blood.2023020722}
}
Kostenlos starten →